251 related articles for article (PubMed ID: 34821953)
21. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
Holland PM; Miller R; Jones J; Douangpanya H; Piasecki J; Roudier M; Dougall WC
Cancer Biol Ther; 2010 Apr; 9(7):539-50. PubMed ID: 20150760
[TBL] [Abstract][Full Text] [Related]
22. Wnt/β-Catenin Signaling Pathway Regulates Osteogenesis for Breast Cancer Bone Metastasis: Experiments in an
Kar S; Jasuja H; Katti DR; Katti KS
ACS Biomater Sci Eng; 2020 May; 6(5):2600-2611. PubMed ID: 33463270
[TBL] [Abstract][Full Text] [Related]
23. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.
Guise TA; Yin JJ; Taylor SD; Kumagai Y; Dallas M; Boyce BF; Yoneda T; Mundy GR
J Clin Invest; 1996 Oct; 98(7):1544-9. PubMed ID: 8833902
[TBL] [Abstract][Full Text] [Related]
24. ITGBL1 Is a Runx2 Transcriptional Target and Promotes Breast Cancer Bone Metastasis by Activating the TGFβ Signaling Pathway.
Li XQ; Du X; Li DM; Kong PZ; Sun Y; Liu PF; Wang QS; Feng YM
Cancer Res; 2015 Aug; 75(16):3302-13. PubMed ID: 26060017
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
[TBL] [Abstract][Full Text] [Related]
26. Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis.
Bachelier R; Confavreux CB; Peyruchaud O; Croset M; Goehrig D; van der Pluijm G; Clézardin P
Int J Cancer; 2014 Sep; 135(6):1319-29. PubMed ID: 24615579
[TBL] [Abstract][Full Text] [Related]
27. Wnt signaling pathway inhibitors as promising diagnostic serum markers of osteolytic bone metastasis.
Galliera E; Marazzi MG; Drago L; Banfi G; Luzzati A; Corsi Romanelli MM
J Biol Regul Homeost Agents; 2016; 30(2):399-408. PubMed ID: 27358126
[TBL] [Abstract][Full Text] [Related]
28. Circulating interleukin-8 levels explain breast cancer osteolysis in mice and humans.
Kamalakar A; Bendre MS; Washam CL; Fowler TW; Carver A; Dilley JD; Bracey JW; Akel NS; Margulies AG; Skinner RA; Swain FL; Hogue WR; Montgomery CO; Lahiji P; Maher JJ; Leitzel KE; Ali SM; Lipton A; Nicholas RW; Gaddy D; Suva LJ
Bone; 2014 Apr; 61():176-85. PubMed ID: 24486955
[TBL] [Abstract][Full Text] [Related]
29. Regulatory roles of miRNAs 16, 133a, and 223 on osteoclastic bone destruction caused by breast cancer metastasis.
Kitayama K; Kawamoto T; Kawakami Y; Hara H; Takemori T; Fujiwara S; Yahiro S; Miyamoto T; Mifune Y; Hoshino Y; Kakutani K; Matsumoto T; Matsushita T; Niikura T; Kuroda R; Akisue T
Int J Oncol; 2021 Nov; 59(5):. PubMed ID: 34713296
[TBL] [Abstract][Full Text] [Related]
30. Osteoblasts suppress high bone turnover caused by osteolytic breast cancer in-vitro.
Krawetz R; Wu YE; Rancourt DE; Matyas J
Exp Cell Res; 2009 Aug; 315(14):2333-42. PubMed ID: 19433087
[TBL] [Abstract][Full Text] [Related]
31. HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway.
Yao Y; Fang ZP; Chen H; Yue L; Min DL; Tang LN; Yu WX; Kung HF; Lin MC; Shen Z
Cancer Gene Ther; 2012 Sep; 19(9):601-8. PubMed ID: 22767217
[TBL] [Abstract][Full Text] [Related]
32. Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysis.
Das S; Samant RS; Shevde LA
J Biol Chem; 2011 Mar; 286(11):9612-22. PubMed ID: 21169638
[TBL] [Abstract][Full Text] [Related]
33. Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancer.
Zinonos I; Luo KW; Labrinidis A; Liapis V; Hay S; Panagopoulos V; Denichilo M; Ko CH; Yue GG; Lau CB; Ingman W; Ponomarev V; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
Int J Oncol; 2014 Aug; 45(2):532-40. PubMed ID: 24865346
[TBL] [Abstract][Full Text] [Related]
34. IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis.
Liang M; Ma Q; Ding N; Luo F; Bai Y; Kang F; Gong X; Dong R; Dai J; Dai Q; Dou C; Dong S
Cell Death Dis; 2019 Apr; 10(5):353. PubMed ID: 31040267
[TBL] [Abstract][Full Text] [Related]
35. Wnt pathway modulators in cancer therapeutics: An update on completed and ongoing clinical trials.
Neiheisel A; Kaur M; Ma N; Havard P; Shenoy AK
Int J Cancer; 2022 Mar; 150(5):727-740. PubMed ID: 34536299
[TBL] [Abstract][Full Text] [Related]
36. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling.
Sung B; Oyajobi B; Aggarwal BB
Mol Cancer Ther; 2012 Feb; 11(2):350-9. PubMed ID: 22090419
[TBL] [Abstract][Full Text] [Related]
37. DHA is a more potent inhibitor of breast cancer metastasis to bone and related osteolysis than EPA.
Rahman MM; Veigas JM; Williams PJ; Fernandes G
Breast Cancer Res Treat; 2013 Oct; 141(3):341-52. PubMed ID: 24062211
[TBL] [Abstract][Full Text] [Related]
38. Runx2 induces bone osteolysis by transcriptional suppression of TSSC1.
Wang DC; Wang HF; Yuan ZN
Biochem Biophys Res Commun; 2013 Sep; 438(4):635-9. PubMed ID: 23933319
[TBL] [Abstract][Full Text] [Related]
39. Melatonin attenuates titanium particle-induced osteolysis via activation of Wnt/β-catenin signaling pathway.
Ping Z; Hu X; Wang L; Shi J; Tao Y; Wu X; Hou Z; Guo X; Zhang W; Yang H; Xu Y; Wang Z; Geng D
Acta Biomater; 2017 Mar; 51():513-525. PubMed ID: 28088671
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway.
Mohammadi-Yeganeh S; Paryan M; Arefian E; Vasei M; Ghanbarian H; Mahdian R; Karimipoor M; Soleimani M
Tumour Biol; 2016 Jul; 37(7):8993-9000. PubMed ID: 26758430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
